Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

AMRN
Amarin Corp Plc
stock NASDAQ ADR

At Close
May 22, 2025 3:59:30 PM EDT
11.00USD+0.182%(+0.02)31,128
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 19, 2025 9:28:30 AM EDT
10.40USD-5.282%(-0.58)0
After-hours
May 22, 2025 4:04:30 PM EDT
10.86USD-1.273%(-0.14)401
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
09:40AM EST  SVB Leerink Maintains Outperform on Amarin Corp, Lowers Price Target to $11   Benzinga
Jan 25, 2022
07:46AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data   Benzinga
Jan 10, 2022
07:12AM EST  Amarin Sees FY21 Sales ~$580M Vs. $596.02M Est.   Benzinga
07:00AM EST  Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 40thAnnual J.P. Morgan Healthcare Conference at which Amarin is scheduled to present virtually on Tuesday, January 11, 2022, at 8:15 am Eastern time.   GlobeNewswire Inc
Jan 4, 2022
07:00AM EST  Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 am ET.   GlobeNewswire Inc
Dec 19, 2021
07:29PM EST  In a release issued under the same headline on Friday, December 17th by Pomerantz LLP, please note that in the second paragraph, the lead plaintiff deadline has been updated from December 21, 2021 to December 23, 2021. The corrected release follows:   GlobeNewswire Inc
Dec 17, 2021
06:19PM EST  Pomerantz Law Firm Announces the Filing of a Class Action Against   GlobeNewswire Inc
Dec 7, 2021
05:03PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Nov 24, 2021
03:51PM EST  Levi & Korsinsky, LLP, Researching Possible Securities Law Violations - Amarin   PR Newswire
Nov 19, 2021
04:47PM EST  'Amarin: 85% Of Doctors Polled At AHA Conference Intend To Prescribe Vascepa' -Seeking Alpha Blog Post From Contributor   Benzinga
Nov 18, 2021
06:21PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Nov 16, 2021
10:28AM EST  Watching Amarin Shares; DealReporter Says Activist Investor May Be Pushing For Sale   Benzinga
08:31AM EST  The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment   Benzinga
07:00AM EST  Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to VASCEPA/VAZKEPA (icosapent ethyl) presented at the American Heart Association (AHA) Scientific Sessions 2021, which took place virtually from November 13-15, 2021.   GlobeNewswire Inc
Nov 15, 2021
05:07PM EST  Amarin Highlights Subgroup Data From REDUCE-IT Shows Benefits Of VASCEPA/VAZKEPA In Patients With Prior Peripheral Artery Disease Presented At Oral Session Presentation For American Heart Association Scientific Sessions Nov. 13-15   Benzinga
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
Nov 11, 2021
07:00AM EST  Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, and Michael Kalb, chief financial officer of Amarin, are scheduled to participate in the following upcoming investor conferences:   GlobeNewswire Inc
Nov 8, 2021
07:00AM EST  Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Three Presentations   GlobeNewswire Inc
Nov 3, 2021
12:01PM EDT  Amarin Corp Earnings Perspective: Return On Capital Employed   Benzinga
09:19AM EDT  The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering   Benzinga
09:13AM EDT  Amarin Corp Q3 EPS $0.03 Beats $(0.03) Estimate, Sales $142.04M Miss $161.96M Estimate   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
06:29AM EDT  Amarin Q3 Loss Per Share $0.03 Vs Loss $0.02 Last Year   RTTNews
06:00AM EDT  Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022   GlobeNewswire Inc
Nov 1, 2021
03:23PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ:AMRN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 25, 2021
07:23PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ:AMRN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 20, 2021
07:05AM EDT  Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarins senior management team to discuss the Company's third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.   GlobeNewswire Inc
Oct 18, 2021
12:55PM EDT  UPDATE: SVB Leerink On Amarin: Firm Sees Europe As 'A Billion-Dollar Market Opportunity For Vazkepa' But Slightly Cautious On U.S. Vascepa Amidst Generic Erosion; Notes 'Early Indicators Show New U.S. Go-To-Market Strategy Is Gaining Traction'   Benzinga
12:54PM EDT  SVB Leerink Reiterates Outperform Rating On Amarin Corporation With $12 Price Target   Benzinga
Sep 25, 2021
11:21AM EDT  TENX: Second Quarter Results   Benzinga
Sep 24, 2021
08:05AM EDT  Cramer Shares His Thoughts On Dynavax, Nucor And Amarin   Benzinga
Sep 22, 2021
09:15AM EDT  Amarin Outlines New Go-To-Market Strategy To Accelerate VASCEPA Growth In US   Benzinga
09:15AM EDT  Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VASCEPA prescriptions for cardiovascular (CV) risk reduction.   GlobeNewswire Inc
Sep 14, 2021
09:37AM EDT  Amarin Pharmaceuticals Granted U.S. Patent Titled 'Methods of reducing the risk of cardiovascular events in a subject'   Benzinga
Sep 13, 2021
07:16AM EDT  Amarin Announces First European Launch Of VAZKEPA In Germany   Benzinga
07:00AM EDT  Amarin Announces First European Launch of VAZKEPA (icosapent   GlobeNewswire Inc
06:00AM EDT  Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021.   GlobeNewswire Inc
Sep 9, 2021
11:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021   Benzinga
06:52AM EDT  SVB Leerink Initiates Coverage On Amarin Corp with Outperform Rating, Announces Price Target of $12   Benzinga
Aug 31, 2021
07:00AM EDT  VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction   GlobeNewswire Inc
Aug 23, 2021
10:23AM EDT  Amarin Early Monday Morning Reported Data From REDUCE-IT Study Showing Vascepa/Vazkepa Reduced Ischemic Events In Patients With Prior Heart Attacks Was Presented At European Society Of Cardiology Congress   Benzinga
03:15AM EDT  VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction   GlobeNewswire Inc
Aug 16, 2021
07:00AM EDT  Latest Clinical Research Evaluating VASCEPA/VAZKEPA   GlobeNewswire Inc
Aug 11, 2021
09:33AM EDT  Amarin Corp Option Alert: Jan, 2023 $5 Calls at the Ask: 266 @ $1.96 vs 7059 OI; Ref=$4.915   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:29AM EDT  Recap: Amarin Q2 Earnings   Benzinga
06:19AM EDT  Amarin Corp Q2 EPS $0.02 Beats $(0.03) Estimate, Sales $154.49M Beat $153.76M Estimate   Benzinga
06:00AM EDT  Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 15, 2021
06:38AM EDT  Amarin to Report Second Quarter and Six Month 2021 Financial   GlobeNewswire Inc
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 21, 2021
12:37PM EDT  Mid-Day Market Update: Crude Oil Rises 1.5%; Tarsus Pharmaceuticals Shares Slide   Benzinga
Jun 2, 2021
04:30PM EDT  Further Insights into Mechanism of Action of Icosapent Ethyl and   GlobeNewswire Inc
May 18, 2021
06:05AM EDT  Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarins senior vice president and head of commercial for Europe and future president and chief executive officer, are scheduled to present at the following investor conferences scheduled in June:   GlobeNewswire Inc
May 17, 2021
04:31PM EDT  Amarin Highlights Presentation Of Scientific Findings For VASCEPA At American College Of Cardiology's 70th Annual Scientific Session   Benzinga
04:05PM EDT  REDUCE-IT patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels   GlobeNewswire Inc
May 15, 2021
08:00AM EDT  Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels   GlobeNewswire Inc
May 12, 2021
10:15AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021   Benzinga
07:45AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:52AM EDT  Goldman Sachs Downgrades Amarin Corp to Sell, Lowers Price Target to $5   Benzinga
May 4, 2021
07:28AM EDT  Amarin To Present Clinical Data And Other Research Results Regarding VASCEPA At American College of Cardiology's 70th Annual Scientific Session May 15-17   Benzinga
07:00AM EDT  Clinical Data and Other Research Results Regarding   GlobeNewswire Inc
Apr 29, 2021
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
07:26AM EDT  Amarin: Q1 Earnings Insights   Benzinga
06:10AM EDT  Amarin Corp Q1 Adj. EPS $0.03 Beats $(0.05) Estimate, Sales $142.20M Miss $147.10M Estimate   Benzinga
06:10AM EDT  Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes   GlobeNewswire Inc
06:00AM EDT  Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP,   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For April 29, 2021   Benzinga
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 22, 2021
10:53AM EDT  Amarin Receives UK Marketing Authorization For VAZKEPA From Medicines, Healthcare Products Regulatory Agency 1, 2   Benzinga
10:53AM EDT  VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3   GlobeNewswire Inc
Apr 20, 2021
06:05AM EDT  Amarin to Report First Quarter Results and Host Conference Call on   GlobeNewswire Inc
Apr 17, 2021
01:51PM EDT  Amarin Presents Further Analyses Of Icosapent Ethyl On Progression Of Coronary Atherosclerosis In EVAPORATE Trial   RTTNews
09:50AM EDT  Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA (icosapent ethyl) on top of statin therapy   GlobeNewswire Inc
Apr 14, 2021
11:51AM EDT  TENX: HELP Results & New Asset to Boot   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 12, 2021
04:32PM EDT  Amarin Announces That Karim Mikhail Will Be The New President And CEO Replacing John Thero On August 1, 2021   Benzinga
04:30PM EDT  John Thero to Retire as President and CEO on August 1, 2021   GlobeNewswire Inc
Apr 6, 2021
06:12AM EDT  Amarin Commences Commercial Initiatives For VAZKEPA In European Union Following Recent Regulatory Approval For Cardiovascular Risk Reduction Indication   Benzinga
06:05AM EDT  Reimbursement dossiers for first 10 countries to be filed in coming months   GlobeNewswire Inc
Mar 30, 2021
10:45AM EDT  Looking Into Amarin Corp's Return On Capital Employed   Benzinga
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
07:17AM EDT  Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl   Benzinga
06:40AM EDT  Amarin Says European Commission Approved Marketing Authorization Application For VAZKEPA   RTTNews
06:25AM EDT  Amarin Receives European Commission Approval For VAZKEPA To Reduce Cardiovascular Risk   Benzinga
06:24AM EDT  Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (150 mg/dL) and other risk characteristics as studied in REDUCE-IT 1, 2   GlobeNewswire Inc
Mar 29, 2021
07:28AM EDT  Amarin's Vascepa Recommended By Canadian Cardiovascular Society For Prevention Of Cardiovascular Diseases   Benzinga
07:09AM EDT  Amarin Highlights Inclusion Of Icosapent Ethyl In Multiple Journals   Benzinga
07:00AM EDT  Recent recommendations or guidances, from Canada and Egypt, expand the global recognition of this important therapy and its demonstrated favorable outcomes study results   GlobeNewswire Inc
Mar 17, 2021
02:18PM EDT  Amarin's Vascepa Associated With Stroke Reduction   Benzinga
11:30AM EDT  28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk   GlobeNewswire Inc
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
05:59AM EST  Amarin Corp Q4 EPS $0.04 Beats $(0.01) Estimate, Sales $167.30M Beat $164.94M Estimate   Benzinga
05:55AM EST  Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact   GlobeNewswire Inc
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
06:05AM EST  Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in February and March:   GlobeNewswire Inc
Feb 17, 2021
08:05AM EST  Amarin to Report Fourth Quarter and Full Year 2020 Results and   GlobeNewswire Inc
Feb 9, 2021
07:02AM EST  Amarin Announces Its Corporate Partner In China, Edding, Has Progressed VASCEPQA Into Commencement Of The Regulatory Review Processes In Mainland China And Hong Kong   Benzinga
07:00AM EST  Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA (icosapent ethyl) into commencement of the regulatory review processes in Mainland China and Hong Kong.   GlobeNewswire Inc
Feb 1, 2021
06:11AM EST  SVB Leerink Maintains Outperform on Amarin Corp, Raises Price Target to $16   Benzinga
Jan 29, 2021
12:56PM EST  Amarian Announces It Receives A Positive CHMP Opinion For Icosapent Ethyl For Cardiovascular Risk Reduction   Benzinga
12:52PM EST  Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT cardiovascular outcomes study   GlobeNewswire Inc
Jan 28, 2021
06:43AM EST  VASCEPA Gets Inclusions In Guidelines From Int'l Medical Societies For Role In Reducing Risk Of Cardiovascular Events   RTTNews
Jan 26, 2021
08:07AM EST  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market   Benzinga
Jan 25, 2021
07:46PM EST  Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit To Include Health Care Insurance Provider   RTTNews
07:35PM EST  Amarin Expands Cardiovascular Risk Reduction Patent Infringement   GlobeNewswire Inc
Jan 22, 2021
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
04:33PM EST  Amarin Reports Chinese Society Of Cardiology Included Icosapent Ethyl In Its Updated Guidelines For Primary Prevention Of Cardiovascular Diseases For 2021   Benzinga
04:30PM EST  Icosapent Ethyl Included in the Chinese Society of Cardiology   GlobeNewswire Inc
Jan 7, 2021
06:21AM EST  Amarin Corporation plc (AMRN) said its full-year 2020 total net revenue are expected to be approximately $610 million, an increase of approximately 42% from prior year. The company said this growth was primarily driven by increased prescription levels of VASCEPA in the United States.   RTTNews
06:09AM EST  Amarin Sees FY20 Sales ~$610M Vs. $619.19M Est.   Benzinga
06:07AM EST  Amarin Sees 2020 Total Net Revenue To Be About $610 Mln   RTTNews
06:05AM EST  Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019   GlobeNewswire Inc
Jan 4, 2021
06:05AM EST  Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 from 2:00 - 2:40 p.m. Eastern Time.   GlobeNewswire Inc
Dec 15, 2020
11:07AM EST  Cramer Shares His Thoughts On Bed Bath & Beyond, Yum Brands And More   Benzinga
Dec 14, 2020
05:00AM EST  REDUCE-IT EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers   GlobeNewswire Inc
Dec 13, 2020
04:27PM EST  Amarin Reported Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA in Late Breaker Presentation at NLA Scientific Sessions 2020   Benzinga
09:52AM EST  Amarin Presents Encouraging Efficacy & Safety Results From Pilot Study Treating COVID-19 Infected Patients With VASCEPA   RTTNews
Dec 12, 2020
09:30PM EST  VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose   GlobeNewswire Inc
Dec 7, 2020
07:11AM EST  Amarin Corporation Announces VASCEPA (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020   Benzinga
07:00AM EST  VASCEPA (Icosapent Ethyl)-Related Scientific Findings   GlobeNewswire Inc
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 30, 2020
08:26PM EST  Amarin Files Patent Infringement Lawsuit Against Hikma   RTTNews
07:55PM EST  Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikmas U.S. affiliate. The lawsuit was filed in the United States District Court in Delaware. A copy of the complaint is available in the FAQ section of Amarins investor relations website.   GlobeNewswire Inc
Nov 24, 2020
06:05AM EST  Amarin to Present at Piper Sandlers 32nd Annual   GlobeNewswire Inc
Nov 20, 2020
10:20AM EST  ROCE Insights For Amarin Corp   Benzinga
08:20AM EST  Amarin Yesterday Shared Topline Data From Partner's Pivotal Phase 3 Study Of VASCEPA In Mainland China   Benzinga
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
Nov 19, 2020
06:30PM EST  Significant Reduction in Triglyceride LevelsWithoutLow-Density Lipoprotein Cholesterol(LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides (>500 mg/dL)   GlobeNewswire Inc
Nov 18, 2020
07:00AM EST  Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effectiveness in reducing major adverse cardiovascular events (MACE) in studied high-risk patients   GlobeNewswire Inc
Nov 16, 2020
10:41AM EST  Amarin Shares Quiet For Earlier Pre-Market Session, Now Up 5.6%; Partner For Vascepa, HLS, Earlier Issued Press Release Highlighting VASCEPA Found To Significantly Reduce Ischemic Events In Patients With Prior Coronary Artery Bypass Grafting Procedures   Benzinga
Nov 13, 2020
10:00AM EST  Amarin Reports VASCEPA Found To 'Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT Study' Presented At American Heart Association Sessions   Benzinga
10:00AM EST  VASCEPA, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events (MACE) in post hoc exploratory analyses of patients with a history of CABG by 24% and 36%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 31%   GlobeNewswire Inc
Nov 11, 2020
04:30PM EST  Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in November:   GlobeNewswire Inc
Nov 5, 2020
09:12AM EST  Looking Into Amarin Corp's Return On Capital Employed   Benzinga
08:54AM EST  Amarin Corp: Q3 Earnings Insights   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
06:05AM EST  Amarin Corp Q3 Adj. EPS $0.01, Inline, Sales $156.50M Beat $154.63M Estimate   Benzinga
06:00AM EST  Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared toSame Periods of 2019 Despite COVID-19 Headwinds   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
06:16PM EST  Notable Earnings Watchlist For Thursday, Nov. 5, 2020 Before Market Open: MUR, ODP, WRK, REGN, ZTS, BLL, CAH, CIR, CBB, ABC, AGIO, AKBA, CMLS, AZN, HBI, CPRI, CNP, CNHI, CRON, GM, HII, NYT, PPL, MLCO, TEVA, BMY, BABA, AAWW, DUK, AMRN, CI, BDX   Benzinga
11:28AM EST  Stocktwits Trending Stocks For Wednesday, Nov. 4, 2020: SPY, LYFT, UBER, SAVA, AMRN, QQQ, ABBV, BLNK, JD, DIA   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 29, 2020
07:01AM EDT  New VASCEPA (Icosapent Ethyl)-Related Scientific   GlobeNewswire Inc
Oct 26, 2020
07:07AM EDT  Amarin Corporation Announces VASCEPAFound to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT Study Presented at ASN Kidney Week 2020.   Benzinga
07:00AM EDT  Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT   GlobeNewswire Inc
Oct 23, 2020
07:05AM EDT  Amarin Highlights Presentation Of Evidence Data At American Society Of Nephrology Kidney Week Oct. 22-25   Benzinga
07:00AM EDT  U.S. Veterans with Decreased Renal Function Shown to Be at Higher   GlobeNewswire Inc
Oct 19, 2020
07:00AM EDT  Amarin to Report Third Quarter 2020 Results and Host Conference   GlobeNewswire Inc
Oct 16, 2020
09:50AM EDT  Looking Into Amarin Corp's Return On Capital Employed   Benzinga
Oct 15, 2020
05:26PM EDT  10 Stocks Moving In Thursday's After-Hours Session   Benzinga
04:32PM EDT  Amarin Highlights Presentation Of REDUCE-IT Study Of VASCEPA   Benzinga
04:30PM EDT  VASCEPA, compared with placebo, significantly reduced primary composite first and total MACE (major adverse cardiovascular events) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 34%   GlobeNewswire Inc
Oct 5, 2020
09:51AM EDT  ROCE Insights For Amarin Corp   Benzinga
07:13AM EDT  Amarin Highlights Upcoming Presentation Of VASCEPA Date At European Atherosclerosis Society Oct. 4-7   Benzinga
07:00AM EDT  Latest Research Evaluating VASCEPA (Icosapent Ethyl)   GlobeNewswire Inc
Sep 28, 2020
08:33AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:06AM EDT  SVB Leerink Maintains Outperform on Amarin Corp, Raises Price Target to $12   Benzinga
Sep 9, 2020
07:00AM EDT  Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 from 11:20 - 11:50 a.m. Eastern Time.   GlobeNewswire Inc
Sep 3, 2020
10:53AM EDT  Amarin CEO, President John Thero Says 'We are extremely disappointed with today's ruling and plan to vigorously pursue available remedies' In Response To ANDA Patent Litigation Ruling   Benzinga
10:52AM EDT  Amarin Provides Update Following Ruling in VASCEPA   GlobeNewswire Inc
09:58AM EDT  Return On Capital Employed Overview: Amarin Corp   Benzinga
09:39AM EDT  Amarin Shares Resume Trading; Move Lower   Benzinga
09:37AM EDT  Amarin Shares Up 2%, Currently Halted On Volatility, Expected To Resume At 9:38:32 a.m. EDT   Benzinga
09:36AM EDT  Amarin Shares Halted On Volatility   Benzinga
09:15AM EDT  Amarin Shares Drop; Co Loses Appeals Court Ruling Over Vascepa   Benzinga
Sep 2, 2020
09:19AM EDT  Amarin Shares Moved Sharply Lower After Judges In Merit Councils Case Named; Sentiment Shows One Judge Of The Three Named Rarely Reverses Lower Court Decisions, Which Is Negative For Co   Benzinga
Sep 1, 2020
04:32PM EDT  Amarin Supports Latest Clinical Research Evaluating VASCEPA In Patients With Persistent Cardiovascular Risk Presented At ESC COngress 2020   Benzinga
04:30PM EDT  VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients   GlobeNewswire Inc
Aug 30, 2020
03:44PM EDT  Amarin's Vascepa Clears Arteries Over Time   Benzinga
08:24AM EDT  The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing   Benzinga
Aug 29, 2020
03:13AM EDT  Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA   GlobeNewswire Inc
Aug 26, 2020
11:17AM EDT  Why Amarin's Stock Is Trading Higher Today   Benzinga
09:42AM EDT  Benzinga's Top Upgrades, Downgrades For August 26, 2020   Benzinga
06:27AM EDT  Piper Sandler Initiates Coverage On Amarin Corp with Overweight Rating, Announces Price Target of $21   Benzinga
Aug 25, 2020
04:22PM EDT  Hearing Piper Sandler Initiated Coverage On Amarin With Overweight Rating And $21 Price Target   Benzinga
Aug 19, 2020
07:06AM EDT  Cramer Gives His Opinion On Livongo Health, DR Horton And More   Benzinga
Aug 17, 2020
07:03AM EDT  Amarin to Present Clinical Research on its VASCPA in Patients with Residual Cardiovascular Risk at the European Society of Cardiology From August 29th Through September 1st   Benzinga
07:00AM EDT  Latest Clinical Research Evaluating VASCEPA (Icosapent   GlobeNewswire Inc
Aug 10, 2020
02:38PM EDT  Dr. Reddy's Receives FDA Approval For Generic Version Of Icosapent Ethyl   Benzinga
Aug 7, 2020
12:13PM EDT  Amarin Supports Investigator-Initiation Trial At Kaiser Permanente In The U.S. To Study Effects Of VASCEPA In Reducing Viral Upper Respiratory Infections, Including Coronavirus And Flu, And the Clinical Severity Of Such Infections   Benzinga
12:12PM EDT  Amarin Supports Investigator-Initiated Trial at Kaiser Permanente   GlobeNewswire Inc
Aug 4, 2020
02:10PM EDT  Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward   Benzinga
09:49AM EDT  Amarin shares are trading higher after the company reported better-than-expected Q2 EPS results.   Benzinga
07:20AM EDT  Recap: Amarin Q2 Earnings   Benzinga
06:46AM EDT  Amarin Announces Plans To 'Maximize Blockbuster Potential of VASCEPA' In Europe   Benzinga
06:38AM EDT  Amarin Plans To Undertake Its Own Focused Commercial Launch Of VASCEPA In Europe   RTTNews
06:30AM EDT  Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades   GlobeNewswire Inc
06:28AM EDT  Amarin Corp Q2 EPS $0.01 Beats $(0.07) Estimate, Sales $135.32M Miss $149.48M Estimate   Benzinga
06:00AM EDT  Total Revenue Increased 34% in Second Quarter 2020 Compared to Second Quarter 2019Despite COVID-19 Headwinds   GlobeNewswire Inc
05:19AM EDT  Earnings Scheduled For August 4, 2020   Benzinga
Jul 27, 2020
07:02AM EDT  VASCEPA Data From REDUCE-IT REVASC, Including New Data On Timeframe To Demonstrated Benefit, Presented As Encore At American Society For Preventitive Cardiology 2020 Virtual Summit   Benzinga
07:00AM EDT  VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study   GlobeNewswire Inc
Jul 21, 2020
04:15PM EDT  Amarin to Report Second Quarter 2020 Results and Host Conference   GlobeNewswire Inc
Jul 20, 2020
04:00PM EDT  Amarin Shares On Watch As Traders Circulate Document 'CADTH Canadian Drug Expert Committee Recommendation' On Vascepa   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC